Question Bank › Young streak off a low base

Young streak off a low base

Young streak off a low base: a short run of consecutive-period improvement has just started, after a stretch that gave i

Calls Tested
488
Answered YES
29
Hit Rate
5.9%
rare by design

UnitedHealth Group Incorporated (UNH) — this company's answers

NO on the Q4 2017 call 2018-01-16 A
The model's full reasoning — Q4 2017 call → NO我们根据提供的财报电话会议记录,判断管理层是否传达了“业务现在已连续几个时期(大约2到4个时期)真正改善,而此前一段时间表现不佳,且这种改善的原因属于公司自身并仍在持续”的信息。 分析要点: 1. 是否有先前不令人满意的时期,以及一个仍然年轻的连续改善期? 2. 改善是否在管理层的表述中是连续且累积的? 3. 原因是否属于公司自身并仍在运行? 在电话会议中,管理层提到了多个业务领域的增长,但我们需要寻找一个具体的、先前表现不佳而现在连续改善的领域。例如,在OptumRx部分,John Prince提到“我们的调整后处方量增长了5%,我们的处方量实际上全年都在加速。所以我们的处方量增长是第四季度全年最高的。”这暗示了连续几个季度的改善,但需要确认是否有先前不令人满意的时期。另外,在UnitedHealthcare的雇主和个人业务中,Jeff Alter提到“我们又有了一季强劲的增长,这已经是连续第13个季度强劲的完全保险团体增长。”这显然是一个长期的良好记录,而不是年轻的改善。 再考虑其他部分,如OptumCare的扩张,但那是战略性的,不是连续改善的表述。在回答中,我们需要找到符合“先前不令人满意”和“年轻连续改善”的明确表述。管理层没有明确提到某个业务之前表现不佳,现在连续改善。相反,他们强调了许多业务的强劲增长,但大多是长期趋势。 例如,在Optum部分,Larry Renfro说“2017年全年Optum收入增长9%,超过910亿美元。2017年运营收益增长近11亿美元,即19%,各业务收益增长率在16%到28%之间。”这显示强劲增长,但没有提到之前的不佳。 在UnitedHealthcare部分,Steve Nelson提到“2017年收入超过1630亿美元,同比增长10%。”同样没有提到之前的不佳。 在回答中,我们需要寻找一个具体的、先前不佳而现在连续改善的叙述。可能是在国际业务或某些特定产品上,但管理层没有明确说“之前不好,现在连续几个季度改善”这样的表述。 在电话会议中,有一个关于“Nexus ACO”产品的提及,但那是新产品,不是连续改善。 另外,在回答中,管理层提到了“我们连续13个季度强劲的完全保险团体增长”,这显然是一个长期记录,不是年轻的改善。 因此,没有找到符合“先前不令人满意”和“年轻连续改善”的明确叙述。管理层主要是在报告强劲的业绩,而不是描述一个从低谷中恢复的年轻趋势。 所以,答案应为NO。

← Back to the full UNH analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management convey that the business has NOW PUT TOGETHER A SHORT, STILL-YOUNG RUN OF CONSECUTIVE PERIODS OF REAL IMPROVEMENT \u2014 roughly two to four periods in a row of getting better \u2014 in a part of the business that, until recently, had been giving investors little reason to expect it, AND that the causes of this young run are attached to the company itself and still in force?\n\nAnswer YES when management's own words convey, in whatever form fits the business, ONE coherent story with all three of the following present:\n\n(1) A PRIOR STRETCH THAT WAS UNIMPRESSIVE, AND A RUN THAT IS STILL YOUNG. It is evident from management's own account that before this run began, the relevant part of the business \u2014 or the company as a whole \u2014 had been weak, flat, declining, stalled, unprofitable, or simply not yet performing: a stretch that would have given an outside observer little basis for optimism. Against that backdrop, management now describes a recent succession of periods \u2014 the just-reported period plus one or more immediately before it \u2014 in which things have gotten better each time: for example, orders, sales, volumes, customers, utilization, output, activity, or profitability improving quarter after quarter for the last few quarters; losses narrowing period by period; a recovery or ramp that has now strung together several consecutive periods of progress; or management noting that this is the second, third, or fourth period in a row of improvement. The run must be YOUNG \u2014 recent enough that management still frames it as a change from what came before, not a long-established record \u2014 and it must be grounded in real, already-occurred results in management's own telling, not in guidance or hopes.\n\n(2) THE IMPROVEMENT IS SEQUENTIAL AND CUMULATIVE IN MANAGEMENT'S OWN FRAMING. Management itself connects the recent periods into one building progression \u2014 each period better than, or building on, the one before \u2014 rather than merely comparing against a year-ago period or describing one good quarter in isolation. The form of the linkage may vary (consecutive-quarter language, month-after-month or period-after-period progression, a count of successive improvements, or a plainly described step-by-step climb), so long as the sequence is management's own account of what has already happened.\n\n(3) THE CAUSE BELONGS TO THE COMPANY AND IS STILL RUNNING. When management explains why the run exists, the explanation rests mainly on things attached to the company itself \u2014 a product or offering now selling, customers won or returning, a fix, change, capability, or capacity the company put in place now working, execution or positioning the company improved \u2014 rather than on commodity prices, industry-wide tailwinds, restocking, or one-time events; AND management conveys, directly or plainly in substance, that these same drivers remain in effect now, so the just-reported period is presented as the latest step of something still climbing rather than the end of a bounce.\n\nAnswer NO if the company has been performing well for a long time, so the recent periods are simply continuation of an established good record rather than a young change from an unimpressive stretch. NO if the call describes only one good or improved period with no succession of consecutive periods behind it. NO if the improvement is only against the year-ago period, only in guidance, or only expected rather than already strung together in reported periods. NO if management attributes the run mainly to external forces \u2014 commodity or market prices, industry recovery, weather, restocking, pull-forward, an easy comparison \u2014 or to one-time items or cost cuts on a shrinking business. NO if management itself presents the run as finished, peaking, or likely to pause. NO if the business is still deteriorating, with improvement only promised. NO if the sequential framing appears only in an analyst's question or model that management does not itself affirm.\n\nUse only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ASO Academy Sports and Outdoors, Inc. Q1 2024 2024-06-11 C+
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
ASB Associated Banc-Corp Q1 2024 2024-04-25 A
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
OLPX Olaplex Holdings, Inc. Q4 2023 2024-02-29 D
MNKD MannKind Corporation Q4 2023 2024-02-27 C
GPRE Green Plains Inc. Q4 2023 2024-02-07 F
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
BMBL Bumble Inc. Q3 2023 2023-11-07 F
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
GOLD Barrick Gold Corporation Q3 2023 2023-11-02 C
OPAD Offerpad Solutions Inc. Q3 2023 2023-11-01 C
TEL TE Connectivity Ltd. Q4 2023 2023-11-01 B
SBRA Sabra Health Care REIT, Inc. Q1 2023 2023-05-04 B
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
TOST Toast, Inc. Q4 2022 2023-02-16 C+
PKOH Park-Ohio Holdings Corp. Q3 2022 2022-11-13 B
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
LC LendingClub Corporation Q4 2021 2022-01-26 A
LEG Leggett & Platt, Incorporated Q3 2021 2021-11-02 C
UFI Unifi, Inc. Q4 2021 2021-08-07 B
ESRT Empire State Realty Trust, Inc. Q2 2021 2021-07-29 C+
LRN Stride, Inc. Q1 2019 2018-10-23 B
ORAN Orange SA Q2 2018 2018-07-26 B
AVT Avnet, Inc. Q2 2018 2018-01-25 B
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
SPR Spirit AeroSystems Holdings, Inc. Q1 2016 2016-04-29 D

How the model reasoned

WRBY · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
ASB · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
KOPN · Q4 2023 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...

More from the question bank

Still getting better as they speakSold out of itselfThe hard part is already doneSecond demand front open and fundedFront, middle, and back of the business all Someone else's clock has started running agaAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.